ArticleJournal of conservative dentistry and endodontics2026
Efficacy of biotene and xerostom on salivary function, biomarkers, and caries risk in radiation-induced xerostomia: A randomized controlled trial.
Article in Journal of conservative dentistry and endodontics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiation-induced xerostomia is a common complication in head and neck cancer (HNC) patients, significantly impairing oral health, nutrition, and quality of life. Salivary substitutes such as Biotene and Xerostom have been developed to manage symptoms, but clinical evidence comparing their effectiveness is limited. Aim: The aim is to evaluate and compare the efficacy of Biotene and Xerostom salivary systems in improving salivary properties and reducing caries susceptibility in postradiotherapy (RT) HNC patients. Methods: Sixty-six patients with radiation-induced xerostomia were randomly assigned to three groups: Biotene ( Results: Both Biotene and Xerostom significantly improved salivary flow (Biotene: 1.26 ± 0.22 mL/min; Xerostom: 1.00 ± 0.25 mL/min) compared to placebo (0.76 ± 0.27 mL/min) at 6 months. pH and buffering capacity also improved in both intervention groups. MUC7 levels were higher in Biotene (77.71 ± 9.38 ng/mL) and Xerostom (74.92 ± 6.76 ng/mL) compared to placebo (61.48 ± 4.96 ng/mL), indicating enhanced mucosal protection. β-defensin-2 levels were lower in treatment groups, suggesting balanced immune activity. Conclusion: Both Biotene and Xerostom improved salivary function, reduced microbial load, and enhanced oral mucosal protection in HNC patients with radiation-induced xerostomia. Biotene demonstrated marginally superior outcomes. These systems may serve as effective interventions for xerostomia management post-RT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.